Sunday, August 1, 2021

Optimus Pharma gets nod for Molnupiravir Phase III trials – ET HealthWorld


Hyderabad: Hyderabad-based Optimus Pharma has received approval from the Indian drug regulator, Drugs Controller General of India (DCGI), for conducting Phase III clinical trials of oral anti-viral drug Molnupiravir on patients with mild to moderate Covid-19 disease.

The company said that the trials will be conducted on as many as 2500 Covid-19 patients suffering from mild and moderate symptoms. The drug will be administered for a period of five days to the volunteers.

“As per the clinical trial protocols approved, total of 2500 subjects in both mild and moderate Covid-19 will be randomised in the study in a 1:1 ratio for Molnupiravir with standard supportive care or standalone standard supportive care. The treatment duration is a maximum of 5 days and the total study duration will be maximum for 29 days from randomisation,” the company said.

Molnupiravir is an experimental anti-viral drug developed for influenza and is now being repurposed for Covid-19.

Follow and connect with us on , Facebook, Linkedin





Source link

Stay Connected

1,605FansLike
11,000FollowersFollow
342FollowersFollow
775FollowersFollow

Latest Articles

Need to create vigilance and awareness on zoonotic diseases: India’s Health Minister

The COVID-19 pandemic has highlighted the need of creating vigilance and awareness on zoonotic diseases, informed Union Health Minister Mansukh Mandaviya while virtually inaugurating...

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...